Rocio Montes de Oca

6PUBLICATIONS
63CO-AUTHORS
Characterisation of biological macromoleculesHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 26, 2025
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4.

Paula Rodríguez-Otero, Surbhi Sidana, Mathilde Kouwenhoven

|Nov 05, 2025
Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.

Junia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman

|Jun 03, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.

Sundar Jagannath, Thomas G Martin, Yi Lin

|Apr 30, 2024
T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.

Christie P M Verkleij, Chloe A O'Neill, Marloes E C Broekmans

|Jul 29, 2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.

Kenneth C Anderson, Daniel Auclair, Stacey J Adam

|Jul 13, 2021
Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo.

Rocio Montes de Oca, Alireza S Alavi, Nick Vitali

Pageof 1

Frequent Collaborators

2 joint publications

Niels Wcj van de Donk

1 joint publications

Alireza S Alavi

1 joint publications

Leslie Obert

1 joint publications

Oliver Kepp